The Banking and Strategy Initiative

Chillin' out till it needs to be funded

Tag Archives: Racivir

Advantage Dealbook: Upending that premium again, Gilead gets HCV portfolio

The culprit of course is another rrich Pharma company saturated with its current mdeicine/ device/service product opr package portfolio. After a J&J bid for Synthes that has ┬ánot progressed and … Continue reading

November 21, 2011 · 2 Comments

Archives